Research updates from Luvaminos
Subscribe for catalog updates, new research compounds, and quality documentation releases.
For researchers and labs. No spam — unsubscribe anytime.
For Research Purposes Only
Out of StockCartalax + BPC-157 + TB-500 + KPV
Third-Party TestedPurity Standards
Total
$104.99Size
Quantity
1
Bundle & Save
Molecular Profile
Molecular Profile
Peptide blend
Cartalax (AED)
Molecular formula
C12H19N3O8
Molecular weight
333.29 g/mol
Sequence
Ala-Glu-Asp
BPC-157
Molecular formula
C62H98N16O22
Molecular weight
1,419.5 g/mol
CAS number
137525-51-0
Sequence
GEPPPGKPADDAGLV
TB-500 (N-acetylated heptapeptide fragment)
Molecular formula
C38H68N10O14
Molecular weight
889.0 g/mol
CAS number
885340-08-9
Sequence
Ac-LKKTETQ
KPV
Molecular formula
C16H30N4O4
Molecular weight
342.43 g/mol
CAS number
67727-97-3
Sequence
Lys-Pro-Val
Mechanism & Target Class
Mechanism & Target Class
This blend combines four structurally and mechanistically distinct molecules. Cartalax (Ala-Glu-Asp; AED) belongs to the class of ultrashort peptide bioregulators studied for proposed nuclear-entry and interaction with histone proteins and DNA promoter sequences, with downstream changes in structural matrix protein transcription examined in cell-culture models. BPC-157 is a 15-residue synthetic peptide whose primary literature maps to the nitric oxide (NO) system and VEGFR2-associated pathways — specifically the VEGFR2–Akt–eNOS and Src–Caveolin-1–eNOS axes — as well as growth-hormone-receptor-linked transcriptional readouts in fibroblast models. TB-500, characterized in the indexed literature as an N-terminally acetylated heptapeptide (Ac-LKKTETQ) corresponding to an actin-binding region within a larger endogenous peptide, is studied in the context of G-actin sequestration and cytoskeletal dynamics; this short sequence and the full-length precursor are not established as equivalent and findings from each are attributed separately. KPV (Lys-Pro-Val) is studied primarily through PepT1 (SLC15A1)-mediated intestinal uptake and downstream NF-κB and MAPK pathway engagement in epithelial and immune cell models. The blend has no single shared molecular target; each component is associated with distinct receptor contexts and signaling programs.
Storage & Handling
Storage & Handling
Lyophilized
20°C for long-term preservation
protect from light and moisture.
Multi-peptide formulation; individual component stabilities vary
References
References
Reviews
- 1
Sikiric P, et al. (2016). Curr Neuropharmacol
- 2
Goldstein AL, Hannappel E, Kleinman HK. (2005). Trends Mol Med
Reviews
- 3
Vasireddi N, et al. (2025). HSS J
- 4
McGuire FP, et al. (2025). Curr Rev Musculoskelet Med
- 5
Khavinson VKh, et al. (2021). Molecules
Primary research
- 6
Chang CH, et al. (2011). J Appl Physiol (1985)
- 7
Dalmasso G, et al. (2008). Gastroenterology
- 8
Khavinson VKh, et al. (2001). Bull Exp Biol Med
- 9
Hsieh MJ, et al. (2020). Sci Rep
- 10
Hsieh MJ, et al. (2017). J Mol Med (Berl)
- 11
Chang CH, et al. (2014). Molecules
- 12
Xiao B, et al. (2017). Mol Ther
- 13
Viennois E, et al. (2016). Cell Mol Gastroenterol Hepatol
- 14
Kannengiesser K, et al. (2008). Inflamm Bowel Dis
- 15
Sun J, et al. (2021). ACS Biomater Sci Eng
- 16
Ho EN, et al. (2012). J Chromatogr A
- 17
Khavinson VKh, et al. (2016). Bull Exp Biol Med
Primary Database
Primary Database
Research Use Only. All products sold by Luvaminos are intended solely for in vitro research and laboratory use by qualified professionals. They are not approved by the FDA and are not intended for human or animal consumption, therapeutic use, or diagnostic purposes. By purchasing, you confirm you are a licensed researcher or institution and accept full responsibility for compliance with all applicable laws and regulations.
